bpc-157 clinicaltrials.gov nct Injectable Peptide for Healing & Recovery Australian Clinical Trials

Keep vials shielded from light, ideally in their original outer packaging

Eloralintide has just entered phase 3 testing, which is typically the final stage of clinical trials before a company can apply for FDA approval

Based on the phase 2 and phase 3 trial protocols: Weeks 1-4: 1 mg once weekly Weeks 5-8: 2 mg once weekly Weeks 9-12: 4 mg once weekly Weeks 13-16: 8 mg once weekly Weeks 17 onward: 12 mg once weekly (maximum dose) The starting dose of retatrutide is deliberately low because the triple-agonist mechanism produces more intense initial side effects than single-pathway compounds

BPC-157 is listed under the World Anti-Doping Agencys S0 category, Non-Approved Substances, which covers any pharmacological substance lacking regulatory approval for human therapeutic use